AI-based differential diagnosis of dementia etiologies on multimodal data.
Chonghua XueSahana S KowshikDiala LteifShreyas PuducheriVaruna H JasodanandOlivia T ZhouAnika S WaliaOsman B GuneyJ Diana ZhangSerena T PhamArtem KaliaevVanessa Carlota Andreu ArasaBrigid C DwyerChad W FarrisHonglin HaoSachin KedarAsim Z MianDaniel L MurmanSarah A O'SheaAaron B PaulSaurabh RohatgiMarie-Helene Saint-HilaireEmmett A SartorBindu N SettyJuan E SmallArun SwaminathanOlga TaraschenkoJing YuanYan ZhouShuhan ZhuCody KarjadiTing Fang Alvin AngSarah A BargalBryan A PlummerKathleen L PostonMeysam AhangaranRhoda AuVijaya B KolachalamaPublished in: Nature medicine (2024)
Differential diagnosis of dementia remains a challenge in neurology due to symptom overlap across etiologies, yet it is crucial for formulating early, personalized management strategies. Here, we present an artificial intelligence (AI) model that harnesses a broad array of data, including demographics, individual and family medical history, medication use, neuropsychological assessments, functional evaluations and multimodal neuroimaging, to identify the etiologies contributing to dementia in individuals. The study, drawing on 51,269 participants across 9 independent, geographically diverse datasets, facilitated the identification of 10 distinct dementia etiologies. It aligns diagnoses with similar management strategies, ensuring robust predictions even with incomplete data. Our model achieved a microaveraged area under the receiver operating characteristic curve (AUROC) of 0.94 in classifying individuals with normal cognition, mild cognitive impairment and dementia. Also, the microaveraged AUROC was 0.96 in differentiating the dementia etiologies. Our model demonstrated proficiency in addressing mixed dementia cases, with a mean AUROC of 0.78 for two co-occurring pathologies. In a randomly selected subset of 100 cases, the AUROC of neurologist assessments augmented by our AI model exceeded neurologist-only evaluations by 26.25%. Furthermore, our model predictions aligned with biomarker evidence and its associations with different proteinopathies were substantiated through postmortem findings. Our framework has the potential to be integrated as a screening tool for dementia in clinical settings and drug trials. Further prospective studies are needed to confirm its ability to improve patient care.